Reduced prevalence of cardiovascular disease and metabolic syndrome-related disorders among Japanese long-term inpatients with schizophrenia
Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increas...
        Saved in:
      
    
          | Published in | Clinical Neuropsychopharmacology and Therapeutics Vol. 6; pp. 16 - 27 | 
|---|---|
| Main Authors | , , , , , , , , , , , , | 
| Format | Journal Article | 
| Language | English | 
| Published | 
            The Japanese Society of Clinical Neuropsychopharmacology
    
        2015
     | 
| Subjects | |
| Online Access | Get full text | 
| ISSN | 1884-8826 1884-8826  | 
| DOI | 10.5234/cnpt.6.16 | 
Cover
| Abstract | Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increase CVD risk. We examined the medical records of long-term inpatients with schizophrenia to identify methods for preventing CVD and MSDs. Method: A retrospective survey was conducted on 56 inpatients with schizophrenia. The prevalence rates of CVD and MSDs among inpatients with schizophrenia were compared with Japanese general population data from the 2010 National Health and Nutrition Examination Survey. Then, we compared the variables influencing CVD and MSDs between first- and second-generation antipsychotic drug groups. Results: The prevalences of hyperlipidemia, diabetes mellitus, hypertension, myocardial infarction, and cerebral hemorrhage among individuals with schizophrenia were lower than those among the Japanese general population. This effect is likely attributable to the nursing care offered to individuals with schizophrenia, which includes dietary advice, moderate exercise support, and body weight and blood pressure measurement. Medication did not correlate with CVD or MSD prevalence. Discussion: Long-term hospitalization appeared to be particularly useful in preventing CVD and MSDs; thus, nursing care equivalent to that provided in hospitals can reduce the prevalence of CVD and MSDs among patients with schizophrenia. Antipsychotic drugs might have only a minor influence on CVD and MSD prevalence with reliable nursing care. Japanese psychiatric personnel should attend to outpatients with schizophrenia, as this population is increasing and receives less care than do inpatients. | 
    
|---|---|
| AbstractList | Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increase CVD risk. We examined the medical records of long-term inpatients with schizophrenia to identify methods for preventing CVD and MSDs. Method: A retrospective survey was conducted on 56 inpatients with schizophrenia. The prevalence rates of CVD and MSDs among inpatients with schizophrenia were compared with Japanese general population data from the 2010 National Health and Nutrition Examination Survey. Then, we compared the variables influencing CVD and MSDs between first- and second-generation antipsychotic drug groups. Results: The prevalences of hyperlipidemia, diabetes mellitus, hypertension, myocardial infarction, and cerebral hemorrhage among individuals with schizophrenia were lower than those among the Japanese general population. This effect is likely attributable to the nursing care offered to individuals with schizophrenia, which includes dietary advice, moderate exercise support, and body weight and blood pressure measurement. Medication did not correlate with CVD or MSD prevalence. Discussion: Long-term hospitalization appeared to be particularly useful in preventing CVD and MSDs; thus, nursing care equivalent to that provided in hospitals can reduce the prevalence of CVD and MSDs among patients with schizophrenia. Antipsychotic drugs might have only a minor influence on CVD and MSD prevalence with reliable nursing care. Japanese psychiatric personnel should attend to outpatients with schizophrenia, as this population is increasing and receives less care than do inpatients. | 
    
| Author | Saitou, Kenichi Inamoto, Atsuko Nakamura, Dan Tani, Masayuki Umezawa, Kaori Takashio, Osamu Hirata, Yosihito Yamada, Hiroki Tamura, Toshiyuki Iwanami, Akira Kato, Nobumasa Ikeda, Ayumi Morita, Tepei  | 
    
| Author_xml | – sequence: 1 fullname: Saitou, Kenichi organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Tani, Masayuki organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Kato, Nobumasa organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Iwanami, Akira organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Yamada, Hiroki organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Nakamura, Dan organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Takashio, Osamu organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Ikeda, Ayumi organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Tamura, Toshiyuki organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Umezawa, Kaori organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Hirata, Yosihito organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Morita, Tepei organization: Department of Psychiatry, Showa University School of Medicine – sequence: 1 fullname: Inamoto, Atsuko organization: Department of Psychiatry, Showa University School of Medicine  | 
    
| BookMark | eNp9kMtKBDEQRYMo-Fz4B9kq9Jj0TKd7cCXiE0EQXTc1lWonkk6aJKOM3-BHGx1fK2tTVZdTl-Jus3XnHTG2L8WoKseTI3RDGqmRVGtsSzbNpGiaUq3_mTfZXoxPIlfViCxusbc70gskzYdAz2DJIXHfcYSgjX-GiAsLgWsTCSJxcJr3lGDmrUEel04H31MRyELKHhnzQVOIHHrvHvk1DOAo39m8FYlCz40bIBlyKfIXk-Y84ty8-mEeyBnYZRsd2Eh7X32HPZyf3Z9eFje3F1enJzcFllKqYlbVIHRTNzNFM1SVmFYTpKkqle46ABRYKiWxnop6WosaSxT1OGtEBLKkarzDDle-i_zN8gWsbYdgegjLVor2I8r2I8pWtVJl-GAFY_AxBur-ZY9X7FNM8Eg_JIRk0NI3KT7pX3UOoSU3fge88pIA | 
    
| Cites_doi | 10.1046/j.1440-1614.2001.00877.x 10.1002/14651858 10.1136/bmj.321.7259.483 10.1016/j.schres.2010.07.012 10.1177/070674379103600401 10.1002/hup.932 10.1192/bjp.171.6.502 10.1093/schbul/sbr148 10.1007/s12529-013-9298-x 10.1093/oxfordjournals.schbul.a033504 10.1017/S0033291798008186 10.1176/appi.ajp.2011.10111609 10.1016/j.ahj.2005.02.007 10.1002/14651858.CD005148.pub2 10.1176/appi.ajp.160.2.284 10.1016/j.pnpbp.2012.01.014 10.1192/bjp.183.6.534 10.1016/j.euroneuro.2005.04.009 10.1111/j.1365-2125.2004.02102.x 10.1192/bjp.bp.109.067512 10.1192/bjp.177.3.212 10.1017/S1121189X00000476 10.1192/bjp.188.2.122 10.1291/hypres.28.901 10.2188/jea.JE20130004  | 
    
| ContentType | Journal Article | 
    
| Copyright | 2015 The Japanese Society of Clinical Neuropsychopharmacology | 
    
| Copyright_xml | – notice: 2015 The Japanese Society of Clinical Neuropsychopharmacology | 
    
| DBID | AAYXX CITATION ADTOC UNPAY  | 
    
| DOI | 10.5234/cnpt.6.16 | 
    
| DatabaseName | CrossRef Unpaywall for CDI: Periodical Content Unpaywall  | 
    
| DatabaseTitle | CrossRef | 
    
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository  | 
    
| DeliveryMethod | fulltext_linktorsrc | 
    
| Discipline | Pharmacy, Therapeutics, & Pharmacology | 
    
| EISSN | 1884-8826 | 
    
| EndPage | 27 | 
    
| ExternalDocumentID | 10.5234/cnpt.6.16 10_5234_cnpt_6_16 article_cnpt_6_0_6_16_article_char_en  | 
    
| GroupedDBID | 53G ABJNI ACGFS ADBBV ALMA_UNASSIGNED_HOLDINGS BAWUL DIK JSF JSH KQ8 OK1 RJT RZJ AAYXX CITATION ADTOC UNPAY  | 
    
| ID | FETCH-LOGICAL-c2116-b57a0d878b6ebc650954ce9626dffaac0c2661c79079707c2c073c26eeea12e53 | 
    
| IEDL.DBID | UNPAY | 
    
| ISSN | 1884-8826 | 
    
| IngestDate | Tue Aug 19 20:50:13 EDT 2025 Tue Jul 01 03:05:36 EDT 2025 Wed Sep 03 06:30:00 EDT 2025  | 
    
| IsDoiOpenAccess | true | 
    
| IsOpenAccess | true | 
    
| IsPeerReviewed | false | 
    
| IsScholarly | false | 
    
| Language | English | 
    
| LinkModel | DirectLink | 
    
| MergedId | FETCHMERGED-LOGICAL-c2116-b57a0d878b6ebc650954ce9626dffaac0c2661c79079707c2c073c26eeea12e53 | 
    
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.jstage.jst.go.jp/article/cnpt/6/0/6_16/_pdf | 
    
| PageCount | 12 | 
    
| ParticipantIDs | unpaywall_primary_10_5234_cnpt_6_16 crossref_primary_10_5234_cnpt_6_16 jstage_primary_article_cnpt_6_0_6_16_article_char_en  | 
    
| ProviderPackageCode | CITATION AAYXX  | 
    
| PublicationCentury | 2000 | 
    
| PublicationDate | 2015 | 
    
| PublicationDateYYYYMMDD | 2015-01-01 | 
    
| PublicationDate_xml | – year: 2015 text: 2015  | 
    
| PublicationDecade | 2010 | 
    
| PublicationTitle | Clinical Neuropsychopharmacology and Therapeutics | 
    
| PublicationTitleAlternate | CNPT | 
    
| PublicationYear | 2015 | 
    
| Publisher | The Japanese Society of Clinical Neuropsychopharmacology | 
    
| Publisher_xml | – name: The Japanese Society of Clinical Neuropsychopharmacology | 
    
| References | [14] Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701. [6] Casadebaig F, Philippe A. Mortality in schizophrenia patients. 3 years follow-up of a cohort. L'Encephale 1999; 25: 329-337. [7] Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121. [18] Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233. [28] Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1: CD005148. doi:10.1002/14651858.CD005148.pub2 [23] Tatsumi Y, Watanabe M, Kokubo Y, Nishimura K, Higashiyama A, Okamura T, Okayama A, Miyamoto Y. Effect of age on the association between waist-to-height ratio and incidence of cardiovascular disease: the Suita study. J Epidemiol 2013; 23: 351-359. [17] Ryan M, Collins P, Thakore J. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160; 284-289. [4] Ösby U, Correia N, Hammar N, Brandt L, Wicks S, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000; 321: 483-484. [8] Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508. [22] Sairenchi T, Iso H, Irie F, Fukasawa N, Yamagishi K, Kanashiki M, Saito Y, Ota H, Nose T. Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. Hypertens Res 2005; 28: 901-909. [9] Lisa D, Peter W, Janine D, Richard G, Leticia P, Alicia L, Anthony L. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-1012. [20] Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008; 23: 283-290. [2] Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15: 399-409. [10] Kubo S, Kotorii T. Systematic intervention for obesity and dyslipidemia in patients with schizophrenia. Jpn J Clin Psychopharmacol 2014;29: 219-224. [13] McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534-539. [27] Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev 2010; 5: CD004412. doi:10.1002/14651858. CD004412.pub2 [5] Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245. [1] Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217. [29] Inagaki A, Tomita M. Novel antipsychotics, antipsychotic polypharmacy and high dose treatment in Japan. Jpn J Clin Psychopharm 2003; 6: 391-401. [16] Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35: 196-202. [25] Kurosawa M, Tensho M, Tanifuji H, Kato T, Uno J, Umeda K, Miwa T, Noda Y, Yoshio T. Prescription survey 2011 of inpatients with schizophrenia in Japan: examination about the new investigation items of BMI and abnormal ECG. Jpn Clin Psychopharmacol 2013; 16: 1041-1050. [11] Mitchell AJ, Vacampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull Published online December 29, 2011; doi: 10.1093/schbul/sbr148. [3] Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-121. [24] Mikami T, Suzuki U, Tajiri M. Kunizuka T, Abe H, Someya T. Effect of admission to the psychiatric ward on the body weight and glucose metabolism of patients with schizophrenia. Jpn J Clin Psychopharmacol 2012; 15: 1857-1862. [15] Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Oveweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 37: 169-175. [12] Gupita A, Craig TK. Diet, smoking and cardiovascular risk in schizophrenia in high and low care supported housing. Epidemiol Psichiatr Soc 2009; 18: 200-207. [21] Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-127. [30] Sim K, Su A, Fujii S, Yang SY, Chong MY, Unqvari GS, Si T, Chung EK, Tsang HY, Chan YH, Heckers S, Shinfuku N, Tan CH. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58: 178-183. [19] Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947-956. [26] Stanley S, Laugharne J. The impact of lifestyle factors on the physical health of people with a mental illness: a brief review. Int J Behav Med 2014; 21: 275-281. 22 23 24 25 26 27 28 29 30 10 11 12 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21  | 
    
| References_xml | – reference: [25] Kurosawa M, Tensho M, Tanifuji H, Kato T, Uno J, Umeda K, Miwa T, Noda Y, Yoshio T. Prescription survey 2011 of inpatients with schizophrenia in Japan: examination about the new investigation items of BMI and abnormal ECG. Jpn Clin Psychopharmacol 2013; 16: 1041-1050. – reference: [7] Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121. – reference: [29] Inagaki A, Tomita M. Novel antipsychotics, antipsychotic polypharmacy and high dose treatment in Japan. Jpn J Clin Psychopharm 2003; 6: 391-401. – reference: [3] Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-121. – reference: [8] Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-508. – reference: [19] Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947-956. – reference: [28] Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1: CD005148. doi:10.1002/14651858.CD005148.pub2 – reference: [20] Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008; 23: 283-290. – reference: [23] Tatsumi Y, Watanabe M, Kokubo Y, Nishimura K, Higashiyama A, Okamura T, Okayama A, Miyamoto Y. Effect of age on the association between waist-to-height ratio and incidence of cardiovascular disease: the Suita study. J Epidemiol 2013; 23: 351-359. – reference: [12] Gupita A, Craig TK. Diet, smoking and cardiovascular risk in schizophrenia in high and low care supported housing. Epidemiol Psichiatr Soc 2009; 18: 200-207. – reference: [5] Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245. – reference: [17] Ryan M, Collins P, Thakore J. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160; 284-289. – reference: [9] Lisa D, Peter W, Janine D, Richard G, Leticia P, Alicia L, Anthony L. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-1012. – reference: [13] McCreadie RG. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183: 534-539. – reference: [2] Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15: 399-409. – reference: [21] Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-127. – reference: [18] Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010; 123: 225-233. – reference: [22] Sairenchi T, Iso H, Irie F, Fukasawa N, Yamagishi K, Kanashiki M, Saito Y, Ota H, Nose T. Age-specific relationship between blood pressure and the risk of total and cardiovascular mortality in Japanese men and women. Hypertens Res 2005; 28: 901-909. – reference: [6] Casadebaig F, Philippe A. Mortality in schizophrenia patients. 3 years follow-up of a cohort. L'Encephale 1999; 25: 329-337. – reference: [24] Mikami T, Suzuki U, Tajiri M. Kunizuka T, Abe H, Someya T. Effect of admission to the psychiatric ward on the body weight and glucose metabolism of patients with schizophrenia. Jpn J Clin Psychopharmacol 2012; 15: 1857-1862. – reference: [1] Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217. – reference: [26] Stanley S, Laugharne J. The impact of lifestyle factors on the physical health of people with a mental illness: a brief review. Int J Behav Med 2014; 21: 275-281. – reference: [30] Sim K, Su A, Fujii S, Yang SY, Chong MY, Unqvari GS, Si T, Chung EK, Tsang HY, Chan YH, Heckers S, Shinfuku N, Tan CH. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58: 178-183. – reference: [16] Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001; 35: 196-202. – reference: [14] Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701. – reference: [11] Mitchell AJ, Vacampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Bull Published online December 29, 2011; doi: 10.1093/schbul/sbr148. – reference: [10] Kubo S, Kotorii T. Systematic intervention for obesity and dyslipidemia in patients with schizophrenia. Jpn J Clin Psychopharmacol 2014;29: 219-224. – reference: [27] Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev 2010; 5: CD004412. doi:10.1002/14651858. CD004412.pub2 – reference: [4] Ösby U, Correia N, Hammar N, Brandt L, Wicks S, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 2000; 321: 483-484. – reference: [15] Gurpegui M, Martínez-Ortega JM, Gutiérrez-Rojas L, Rivero J, Rojas C, Jurado D. Oveweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 37: 169-175. – ident: 16 doi: 10.1046/j.1440-1614.2001.00877.x – ident: 27 doi: 10.1002/14651858 – ident: 4 doi: 10.1136/bmj.321.7259.483 – ident: 18 doi: 10.1016/j.schres.2010.07.012 – ident: 5 doi: 10.1177/070674379103600401 – ident: 20 doi: 10.1002/hup.932 – ident: 10 – ident: 8 doi: 10.1192/bjp.171.6.502 – ident: 11 doi: 10.1093/schbul/sbr148 – ident: 26 doi: 10.1007/s12529-013-9298-x – ident: 9 doi: 10.1093/oxfordjournals.schbul.a033504 – ident: 14 doi: 10.1017/S0033291798008186 – ident: 19 doi: 10.1176/appi.ajp.2011.10111609 – ident: 7 doi: 10.1016/j.ahj.2005.02.007 – ident: 28 doi: 10.1002/14651858.CD005148.pub2 – ident: 24 – ident: 17 doi: 10.1176/appi.ajp.160.2.284 – ident: 15 doi: 10.1016/j.pnpbp.2012.01.014 – ident: 13 doi: 10.1192/bjp.183.6.534 – ident: 2 doi: 10.1016/j.euroneuro.2005.04.009 – ident: 30 doi: 10.1111/j.1365-2125.2004.02102.x – ident: 29 – ident: 3 doi: 10.1192/bjp.bp.109.067512 – ident: 1 doi: 10.1192/bjp.177.3.212 – ident: 12 doi: 10.1017/S1121189X00000476 – ident: 21 doi: 10.1192/bjp.188.2.122 – ident: 22 doi: 10.1291/hypres.28.901 – ident: 6 – ident: 23 doi: 10.2188/jea.JE20130004 – ident: 25  | 
    
| SSID | ssj0000580884 | 
    
| Score | 1.5549601 | 
    
| Snippet | Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the... | 
    
| SourceID | unpaywall crossref jstage  | 
    
| SourceType | Open Access Repository Index Database Publisher  | 
    
| StartPage | 16 | 
    
| SubjectTerms | antipsychotic drugs cardiovascular disease metabolic syndrome-related disorders nursing care schizophrenia  | 
    
| Title | Reduced prevalence of cardiovascular disease and metabolic syndrome-related disorders among Japanese long-term inpatients with schizophrenia | 
    
| URI | https://www.jstage.jst.go.jp/article/cnpt/6/0/6_16/_article/-char/en https://www.jstage.jst.go.jp/article/cnpt/6/0/6_16/_pdf  | 
    
| UnpaywallVersion | publishedVersion | 
    
| Volume | 6 | 
    
| hasFullText | 1 | 
    
| inHoldings | 1 | 
    
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Clinical Neuropsychopharmacology and Therapeutics, 2015, Vol.6, pp.16-27 | 
    
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1884-8826 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000580884 issn: 1884-8826 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1884-8826 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000580884 issn: 1884-8826 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher  | 
    
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED_WdLDtYd1Hy7Kt5ehGnyrHSSTZeSxjpXSspKOB7MnI-ihtM8fUDiP7G_ZH7xQrTVoYjD0Zm7Ms7oTufufT7wA-GicMuVnOVNcmjEsTM0UogClnyBvapK-VT-h_PZMnI346FuOQuqhCWeU1xUWX1l-iy2l0XXaCEju6KOuOJBQvs67sZKVxG7ApBQXhLdgcnQ2Pvnt4laacUdwoGx4hAlp88WIkI9_UfM37PG4-9AyezIpSzX-qyWTNtxxvwXg5q6ak5Caa1Xmkfz0gbPyPab-A5yHexKNG6CU8ssUrOBg2hNXzQ7xYnb-qDvEAhysq6_lr-P3NM7tag-WtpwX3uwBOHep7RawYfvKgKgz-sDUtq8mVxiUXAlscl6ExTCD6rHDR4QhPyU_7_pc4oTvmXQReFYHntUKfIMZqvSRwG0bHny8-nbDQv4FpgpWS5SJRsUmTNJc2156qT3BtBwShjHNK6Vj76EAnhM8HSZzonqb9hp5Za1W3Z0V_B1rFtLBvAFOrCMj1jLJCcpmLPMmdlTwVjuuB68s27C_tmpUNTUdG8MYbP_Pqz7zq28AbG92JBAstReKF2OopaZw2jzZ8uFsffx_87T9JvYOnFHGJJofzHlr17czuUlRT53uw8eU83Qvr-A9BTQOY | 
    
| linkProvider | Unpaywall | 
    
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-2dLDtod1Hx9KPcbSjT5XjJJLsPJbSUgorYTSQPRlZH6Vt6pjaYWR_w_7onWKlyQaDsSdjc5bFndDd73z6HcBn44QhN8uZ6tqEcWlipggFMOUMeUOb9LXyCf0vV_JixC_HYhxSF1Uoq7yjuOjG-kt0M43uyk5QYkcXZd2RhOJl1pWdrDTuOWxIQUF4CzZGV8OTbx5epSlnFDfKhkeIgBZfvBjJyDc1X_M-L5oPvYaXs6JU8-9qMlnzLedbMF7OqikpuY9mdR7pH38QNv7HtN_AZog38aQRegvPbPEOjoYNYfX8GK9X56-qYzzC4YrKev4efn71zK7WYPnoacH9LoBTh_q3IlYMP3lQFQYfbE3LanKrccmFwBbHZWgME4g-K1x0OMJL8tO-_yVO6I55F4G3ReB5rdAniLFaLwnchtH52fXpBQv9G5gmWClZLhIVmzRJc2lz7an6BNd2QBDKOKeUjrWPDnRC-HyQxInuadpv6Jm1VnV7VvQ_QKuYFvYjYGoVAbmeUVZILnORJ7mzkqfCcT1wfdmGg6Vds7Kh6cgI3njjZ179mVd9G3hjoyeRYKGlSLwQWz0ljdPm0YbDp_Xx98F3_klqF15RxCWaHM4etOrHmd2nqKbOP4UV_AsxeAKj | 
    
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduced+prevalence+of+cardiovascular+disease+and+metabolic+syndrome-related+disorders+among+Japanese+long-term+inpatients+with+schizophrenia&rft.jtitle=Clinical+Neuropsychopharmacology+and+Therapeutics&rft.au=Saitou%2C+Kenichi&rft.au=Tani%2C+Masayuki&rft.au=Kato%2C+Nobumasa&rft.au=Iwanami%2C+Akira&rft.date=2015&rft.pub=The+Japanese+Society+of+Clinical+Neuropsychopharmacology&rft.eissn=1884-8826&rft.volume=6&rft.spage=16&rft.epage=27&rft_id=info:doi/10.5234%2Fcnpt.6.16&rft.externalDocID=article_cnpt_6_0_6_16_article_char_en | 
    
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1884-8826&client=summon | 
    
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1884-8826&client=summon | 
    
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1884-8826&client=summon |